Francesca Negri & Camillo Porta. (2021). Donafenib in Chinese patients with advanced hepatocellular carcinoma (HCC): Really a new standard of care, or should we change paradigm for drug development in HCC? Frontiers Media S.A..
Chicago Style (17th ed.) CitationFrancesca Negri and Camillo Porta. Donafenib in Chinese Patients with Advanced Hepatocellular Carcinoma (HCC): Really a New Standard of Care, or Should We Change Paradigm for Drug Development in HCC? Frontiers Media S.A., 2021.
MLA (9th ed.) CitationFrancesca Negri and Camillo Porta. Donafenib in Chinese Patients with Advanced Hepatocellular Carcinoma (HCC): Really a New Standard of Care, or Should We Change Paradigm for Drug Development in HCC? Frontiers Media S.A., 2021.
Warning: These citations may not always be 100% accurate.